✨ Free AI Report
Surface Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Surface Oncology, Inc.
Company Research

Surface Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Surface Oncology is a clinical-stage, immuno-oncology company focused on developing immunotherapies that target the tumor microenvironment. The company targets cancer patients through novel antibody candidates designe...

Analyst-debate audio for Surface Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Surface Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Early-stage immuno-oncology plays with unproven therapies and limited resources face high execution and dilution risk in a...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Surface Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Surface Oncology, Inc. Overview

Pro stress-test →

Surface Oncology is a clinical-stage, immuno-oncology company focused on developing immunotherapies that target the tumor microenvironment. The company targets cancer patients through novel antibody candidates designed to enhance immune responses against tumors.

Strategic Profile

Pro stress-test →

Surface Oncology operates two wholly-owned clinical-stage programs targeting IL-27 (SRF388) and CCR8 (SRF114), plus partnerships with Novartis targeting CD73 and GlaxoSmithKline targeting PVRIG. As a pre-revenue clinical-stage company, execution in clinical trials and regulatory progression represent the primary value drivers and execution risks.

Competitive Landscape

Pro stress-test →

Surface Oncology competes in immuno-oncology against established players like Jounce Therapeutics, Calithera Biosciences, and larger pharmaceutical companies expanding into checkpoint and immunosuppression pathways. The company's earlier-stage profile and limited capitalization place it at a disadvantage against well-funded competitors with advanced pipelines and commercial infrastructure.

Industry Context

Surface Oncology, Inc. operates in Oncology Drugs.

Key facts

Founded: 2014 · Headquarters: Cambridge, US · Employees: Unknown · Revenue: Estimated $0 (pre-commercial, clinical-stage) · Market cap: $65.08M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Surface Oncology, Inc..

  • Market cap of $65.08M with 60.82M shares outstanding. Stock trading near 52-week low signals limited investor confidence in pipeline advancement and capital runway sustainability.
  • Company developing multiple antibody candidates targeting innate and adaptive immunity barriers, with lead programs SRF388 (IL-27) and SRF114 (CCR8). Pipeline breadth requires significant capital; limited market cap suggests funding constraints.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KeytrudaAnti-PD-1 checkpoint inhibitor for immuno-oncology→OpdivoAnti-PD-1 checkpoint inhibitor and combination therapies→LibtayoAnti-PD-L1 checkpoint inhibitor→Jounce PlatformImmuno-oncology targeting tumor microenvironment→

Compare Surface Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Surface Oncology, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Surface Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Surface Oncology, Inc. and its top competitor on Cyborg Score”
“What did Surface Oncology, Inc. do this quarter?”
“Is Surface Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Surface Oncology, Inc. do?+
Surface Oncology is a clinical-stage, immuno-oncology company focused on developing immunotherapies that target the tumor microenvironment. The company targets cancer patients through novel antibody candidates designe...
What is Surface Oncology, Inc.'s Cyborg Score?+
Surface Oncology, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Surface Oncology, Inc.'s main competitors?+
Named competitors include Keytruda, Opdivo, Libtayo, Jounce Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Surface Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Surface Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Surface Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.